STOCK TITAN

Ardelyx Inc - ARDX STOCK NEWS

Welcome to our dedicated news page for Ardelyx (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.

Rhea-AI Summary
Ardelyx, Inc. (ARDX) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference. The biopharmaceutical company aims to develop innovative medicines to address unmet medical needs. Management will discuss at 2:30 p.m. E.T. on November 29, 2023, in New York City. Webcast available on Ardelyx's Investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
-
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) announced that the FDA granted Orphan Drug Designation to XPHOZAH® (tenapanor) for pediatric hyperphosphatemia. XPHOZAH is a first-in-class medicine that blocks phosphate absorption. The designation supports the development of new drugs for rare diseases, providing potential market exclusivity for seven years after approval, exemption from user fees, and tax credits for qualified clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
clinical trial
-
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) announced the resignation of Dr. Geoffrey Block from the Board of Directors after nearly five years of service. Dr. Block is the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care. The company expressed gratitude for Dr. Block's contributions and highlighted his role in Ardelyx's evolution from a developmental, clinical-stage biopharmaceutical company to an established commercial entity. Dr. Block emphasized Ardelyx's favorable position following the U.S. FDA approval of XPHOZAH® (tenapanor), a phosphate absorption inhibitor for chronic kidney disease patients on dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
management
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) to participate in fireside chat at Jefferies London Healthcare Conference. Management to present at 8:30 a.m. GMT in London, UK. Webcast available on Ardelyx website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Ardelyx, Inc. has announced that XPHOZAH, the first and only FDA approved phosphate absorption inhibitor, is now available for shipment to partner pharmacies. XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis. It is a single tablet taken twice daily with a first-in-class mechanism of action that blocks phosphate absorption. Ardelyx will integrate XPHOZAH into its patient services program, ArdelyxAssist, which provides access and affordability support for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. shared positive data on the use of XPHOZAH® (tenapanor) at the American Society of Nephrology Kidney Week 2023 meeting. XPHOZAH is the first phosphate absorption inhibitor approved by the FDA to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The data presented highlighted improved serum phosphate control and patient-reported quality of life, as well as a reduction in pill burden. Patient education was found to improve adherence to tenapanor treatment. A safety analysis showed that tenapanor has an acceptable safety and tolerability profile in patients with CKD on maintenance dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
Rhea-AI Summary
Ardelyx, Inc. reported Q3 net sales revenue of $22.3 million for IBSRELA, a 22% increase compared to Q2. They expect 2023 full-year IBSRELA U.S. net sales revenue to be $76-78 million. XPHOZAH received FDA approval on October 17 and the company expects to have it available in early November. The company ended Q3 with $165.1 million in cash, cash equivalents, and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.12%
Tags
earnings
-
Rhea-AI Summary
Ardelyx, Inc. has granted options and restricted stock units (RSUs) to non-executive employees. The options allow the purchase of 635,024 shares of common stock at exercise prices of $3.54 and $3.49 per share. The RSUs total 591,900 shares. The stock options and RSUs were granted as inducements for employment and vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.12%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. will present positive data on IBSRELA (tenapanor) at the American College of Gastroenterology annual meeting. The data shows a quick onset of symptom relief and increased response rates with continued therapy. Tenapanor improves abdominal symptoms independent of changes in bowel movement frequency and reduces bloating. The company is sponsoring a Product Theater to discuss clinical considerations and share efficacy and safety data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
none
Rhea-AI Summary
Ardelyx, Inc. to hold conference call for third quarter financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
conferences earnings
Ardelyx Inc

Nasdaq:ARDX

ARDX Rankings

ARDX Stock Data

1.72B
226.69M
1.88%
59.7%
14.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fremont

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.